Loading...
Please wait, while we are loading the content...
Similar Documents
Basal ganglia structure and the effects of neuroleptic treatment in schizophrenia
| Content Provider | Semantic Scholar |
|---|---|
| Author | Lang, Donna |
| Copyright Year | 2002 |
| Abstract | Schizophrenia is a complex mental illness of unknown etiology. Clinical research has suggested that abnormalities of the basal ganglia are present in schizophrenia. Whether these abnormalities are present at the beginning of illness or progress with time remains controversial. Concomitantly, antipsychotic treatments, particularly traditional neuroleptics, may exert metabolic effects on the basal ganglia, but the effects of new atypical antipsychotic are unknown. To elucidate the nature of underlying basal ganglia structure and the effects of antipsychotic treatment on striatal morphology, clinical signs and symptoms, three MRI studies of basal ganglia volumes were conducted. In study A, baseline volumes in a cohort of drug-naive first episode psychosis (FEP) patients, chronically treated schizophrenia patients and healthy controls were assessed. Chronically treated patients had larger basal ganglia volumes compared to both never-medicated patients and healthy controls. Never-medicated patients' basal ganglia volumes were not different from controls. In study B, extrapyramidal symptoms (EPS) and their relationship to neuroleptics and striatal volumes were examined. Prior to neuroleptic treatment, 39% of FEP patients had EPS at baseline. FEP patients who presented with parkinsonism had larger left caudate volumes than those who |
| File Format | PDF HTM / HTML |
| DOI | 10.14288/1.0090594 |
| Alternate Webpage(s) | https://open.library.ubc.ca/media/download/pdf/831/1.0090594/1 |
| Alternate Webpage(s) | https://doi.org/10.14288/1.0090594 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
